{"entity":{"id":"nct05765032","kind":"trial","name":"Study of SHR-A1921 in Combination With Other Anti-cancer Agents in Patients With Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of SHR-A1921 in advanced solid tumours, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., active and no longer recruiting.","summary":"Study of SHR-A1921 in Combination With Other Anti-cancer Agents in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05765032 by Suzhou Suncadia Biopharmaceuticals Co., Ltd., with 220 participants enrolled, started 2022-12-30 and due to reach its primary completion in 2025-04-30. Interventions recorded: SHR-A1921；.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05765032","url":"https://clinicaltrials.gov/study/NCT05765032"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["shr-a1921"],"companies":["hengrui"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05765032","phase":"1/2","setting":"An Open Label, Multicenter, Phase Ib/II Study of SHR-A1921 in Combination With Other Anti-cancer Agents in Patients With Advanced Solid Tumors","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","enrolled":220,"outcomes":[]},"route":"/trials/nct05765032/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"shr-a1921","kind":"drug","name":"SHR-A1921","route":"/drugs/shr-a1921/"}],"company":[{"id":"hengrui","kind":"company","name":"Jiangsu Hengrui Pharmaceuticals","route":"/companies/hengrui/"}]}}